Investigating efficacy of ERB Agonists in Therapy-Resistant, ERa+ Breast Cancer
Loading...
Date
2022-05
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
The Ohio State University
Abstract
Breast cancer is one of the leading causes of death by cancer in women worldwide. In the United States alone, over 40,000 women die from cancer each year. Although there have been advances in the diagnostic procedures and improved therapies, breast cancer prevalence and mortality rates continue to rise globally. Thus, extensive research continues to be conducted towards developing breast cancer therapies in an effort to improve patient outcomes. Most breast cancers are estrogen receptor alpha positive (ERa+) and human epidermal growth factor receptor-2 negative (HER2-). This cancer subtype can be treated with hormonal treatment, commonly known as endocrine therapy. However, a critical challenge with endocrine therapy is the development of resistance in breast cancer patients. Therefore, there is a critical need to develop a novel therapeutic approach that can overcome resistance and inhibit disease progression. The Cherian Lab at The Ohio State University has conducted extensive preliminary research on the role of estrogen receptor beta (ERB) in breast cancer and has found several studies that show evidence of its tumor suppressive role in many biological contexts. Although the gene that codes for this receptor, ESR2, has been discovered many years ago, there has been a limited of number studies that explore the effects of targeting this gene due to the lack of highly selective ERB agonists. Our institution recently developed a highly selective agonist known as OSU-ERb-12. This study investigates the efficacy of OSU-ERb-12 in inhibiting the progression of preclinical models of breast cancer, with a particular focus on therapy-resistant breast cancers.
Description
Keywords
Breast Cancer, ERB agonists, Therapeutic potential, Resistance
Citation
Datta J, Willingham N, Manouchehri JM, et al. Activity of estrogen receptor β agonists in therapy-resistant estrogen receptor-positive breast cancer. Front. Oncol.12:857590. https://doi.org/10.3389/fonc.2022.857590